Vyleesi Cost in Wyoming 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is Bremelanotide and Why Does It Cost So Much?

Bremelanotide is a melanocortin receptor agonist approved by the FDA on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Sold as Vyleesi by Palatin Technologies and AMAG Pharmaceuticals (now Cosette Pharmaceuticals), it is the only on-demand pharmacologic treatment for HSDD. Addyi (flibanserin), the other FDA-approved HSDD drug, requires daily dosing; bremelanotide does not.

How the Drug Works

Bremelanotide activates MC1R, MC3R, and MC4R melanocortin receptors in the central nervous system [2]. This activity is thought to modulate dopaminergic and serotoninergic pathways tied to sexual motivation. The auto-injector delivers 1.75 mg subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. Patients should not use it more than once per 24 hours and no more than eight times per month per the prescribing information [1].

Why the List Price Is $1,200

Single-source branded drugs with no generic equivalent typically carry list prices set to recover research and development costs quickly. Palatin Technologies spent over a decade developing bremelanotide through Phase I, II, and III programs. With no competitor molecule approved for the same indication and on-demand mechanism, there is no market pressure to reduce list price. Wyoming has no state pharmaceutical price-transparency law that would force public reporting of net prices after manufacturer rebates.

Vyleesi Cash Price in Wyoming in 2026

The manufacturer list price for Vyleesi is $1,200 per month in 2026, and that number does not change meaningfully at Wyoming retail chains. GoodRx and similar discount aggregators offer coupons that reduce the price at select pharmacies, but savings are modest and typically land between $980 and $1,150 per fill rather than approaching the compounded alternative's price point.

Retail Pharmacy Pricing

At major Wyoming retail chains (Smith's, Walmart, Walgreens, and independent pharmacies in Cheyenne, Casper, and Laramie), the cash price without any coupon or card is $1,200 for a single auto-injector carton. One carton contains one 1.75 mg device. Because the drug is used as-needed rather than daily, some patients use fewer than one carton per month, which can reduce monthly spend if sexual activity is infrequent.

Mail-Order Pharmacy Options

Specialty mail-order pharmacies that ship to Wyoming may offer slightly lower prices when using manufacturer coupons stacked with pharmacy discount programs. However, Vyleesi requires a valid Wyoming-licensed prescriber order, and some specialty pharmacies require enrollment verification before shipping. Processing times average 3 to 7 business days after prescription receipt [1].

GoodRx and Similar Aggregators

GoodRx coupons for bremelanotide in Wyoming show prices ranging from approximately $970 to $1,150 at participating pharmacies. These coupons cannot be combined with insurance, Medicaid, or the Palatin manufacturer savings card. Patients should compare the GoodRx coupon price against the manufacturer card price at the time of fill, because the better deal shifts depending on the pharmacy's contracted rate.

Wyoming Medicaid Coverage for Vyleesi

Wyoming Medicaid does not cover bremelanotide. The Wyoming Department of Health Medicaid program excludes Vyleesi from its preferred drug list, and no prior authorization pathway currently exists for this drug in the Wyoming Medicaid formulary [3]. This coverage gap affects roughly 83,000 Wyoming residents enrolled in Medicaid as of fiscal year 2024 [4].

Why Medicaid Excludes It

State Medicaid programs have broad latitude to exclude drugs they classify as lifestyle medications or drugs lacking sufficient cost-effectiveness evidence. The Institute for Clinical and Economic Review (ICER) published an evidence report on HSDD treatments noting that the clinical effect sizes for bremelanotide, while statistically significant, are modest in absolute terms [5]. Wyoming Medicaid formulary committees weigh those effect sizes against the $1,200 list price when making coverage decisions.

Medicaid Managed Care Plans in Wyoming

Wyoming operates a fee-for-service Medicaid model rather than a managed care organization (MCO) model for most beneficiaries. There is no secondary MCO formulary that might independently cover Vyleesi. Patients on Medicaid who need HSDD treatment should ask their prescriber about off-label options or refer to a sexual medicine specialist who may document medical necessity for an appeal, though approvals remain rare.

Commercial Insurance Coverage for Vyleesi in Wyoming

Commercial insurance coverage for bremelanotide in Wyoming is inconsistent and requires prior authorization at virtually every plan. The most common commercial insurers operating in Wyoming include Blue Cross Blue Shield of Wyoming, UnitedHealthcare, Aetna, and Cigna [6].

Prior Authorization Criteria

Most Wyoming commercial plans apply the following prior authorization criteria before approving Vyleesi:

• Confirmed diagnosis of acquired, generalized HSDD in a premenopausal woman
• Documentation that the low desire is not caused by a relationship problem, another medical condition, or a medication side effect
• Prescriber attestation that the patient has been counseled on the drug's side-effect profile, particularly nausea (occurring in 40.4% of patients in RECONNECT) and transient blood pressure increases [7]
• Sometimes a requirement to trial and fail a non-pharmacologic intervention first

Even when these criteria are met, denial rates are high. Patients who receive a denial have the right to an internal appeal and, if that fails, an external independent review under Wyoming Insurance Department rules [6].

The Palatin Technologies Savings Card

Palatin Technologies (the manufacturer) offers a savings card for commercially insured patients that may reduce out-of-pocket cost to $0 per month, subject to program terms and eligibility. The card is not valid for patients using Medicare, Medicaid, or any other government-funded program. Wyoming patients can enroll at the Vyleesi manufacturer website or through their prescribing clinician's office. The savings card typically covers up to $200 per fill, applied after the insurance adjudication, so the patient's copay is zeroed out if the plan covers the drug and the patient's remaining cost is $200 or less. Patients whose plans deny coverage entirely do not benefit from this card and pay the full cash price minus any coupon [1].

Compounded Bremelanotide in Wyoming: Legality and Cost

Compounded bremelanotide is legally available in Wyoming through 503A compounding pharmacies operating under state and federal law. The drug is NOT on the FDA's list of drugs that may not be compounded, and bremelanotide's active pharmaceutical ingredient (API) is commercially available to licensed compounders [8].

The HealthRX clinical team uses the following decision framework when counseling Wyoming patients on brand vs. Compounded bremelanotide:

1. If the patient has commercial insurance with a realistic path to coverage (no prior denials, diagnosis clearly documented), pursue brand Vyleesi with the savings card first.
2. If insurance has already denied, or if the patient is uninsured or on Medicaid, compounded bremelanotide at ~$140/month is the evidence-informed cost-effective choice, provided the pharmacy is 503A-licensed and uses sterile compounding practices.
3. If the patient is immunocompromised or has a history of injection-site reactions, consult a sexual medicine specialist before initiating either formulation.

What 503A Means

A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed practitioner. These pharmacies are regulated by state boards of pharmacy, including the Wyoming State Board of Pharmacy, and must comply with USP <797> standards for sterile compounding [8]. They are not required to obtain FDA approval for each compounded preparation, but they may not compound copies of commercially available drugs without documentation of a clinical difference or patient-specific need.

Is Compounded Bremelanotide the Same Drug?

Compounded bremelanotide uses the same active peptide sequence as Vyleesi. However, excipients, preservatives, and sterility validation differ between compounders, so quality is not uniform across all 503A pharmacies. Patients should ask any compounding pharmacy for its certificate of analysis (COA) for the bremelanotide API batch and for documentation of sterility testing on the finished preparation.

Compounded Cost in Wyoming

Licensed 503A pharmacies serving Wyoming patients charge approximately $140 per month for a supply of compounded bremelanotide in multi-dose vials or unit-dose syringes. This represents an 88% cost reduction compared to the $1,200 brand list price. Patients using compounded options through telehealth platforms may pay a combined consultation-plus-medication fee; verify the itemized breakdown before enrollment.

Clinical Evidence: What the RECONNECT Trials Found

The FDA approved bremelanotide based primarily on two Phase III randomized controlled trials called RECONNECT [7]. Understanding this evidence helps patients and prescribers frame realistic expectations alongside the cost conversation.

RECONNECT Trial Design

RECONNECT enrolled 1,267 premenopausal women with acquired, generalized HSDD across two parallel trials (Study 301 and Study 302). Participants were randomized 1:1 to bremelanotide 1.75 mg subcutaneous or placebo, self-administered as needed over 24 weeks [7].

Key Efficacy Findings

The co-primary endpoints were the Female Sexual Function Index desire domain (FSFI-D) score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. Bremelanotide produced statistically significant improvements on both endpoints compared to placebo (P<0.001 for both co-primary endpoints in each trial) [7]. The proportion of women reporting a clinically meaningful improvement in desire was approximately 25% in the bremelanotide arm versus 17% in placebo, an absolute difference that clinicians should communicate clearly to patients so expectations are calibrated before a $1,200/month expenditure is committed.

Safety Profile Relevant to Wyoming Patients

Nausea occurred in 40.4% of bremelanotide-treated women versus 1.3% of placebo patients [7]. Flushing was reported in 20.4% of the active arm. Transient increases in systolic blood pressure averaging 6 mmHg peak at approximately 12 minutes post-injection were observed; blood pressure returned to baseline within 12 hours in most participants [2]. Women with uncontrolled hypertension or known cardiovascular disease should not use bremelanotide per the prescribing label [1].

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that "treatment of HSDD with pharmacologic agents should be considered only after a comprehensive biopsychosocial assessment has been completed and non-pharmacologic options have been discussed" [9]. Wyoming clinicians using telehealth to prescribe bremelanotide are expected to meet this standard.

Telehealth Prescribing of Vyleesi in Wyoming

Wyoming allows telehealth prescribing of bremelanotide, provided the prescriber holds an active Wyoming medical license or meets Wyoming's telehealth practice standards under Wyoming Statute Section 33-26-102 [10]. Wyoming is a member of the Interstate Medical Licensure Compact (IMLC), which allows physicians licensed in other compact states to obtain Wyoming licensure more quickly, expanding the pool of telehealth providers available to Wyoming residents [10].

What a Telehealth Visit for Vyleesi Looks Like

A synchronous audio-video visit is typically required for a new HSDD evaluation, though Wyoming does not mandate audio-video specifically for this indication. The prescriber will take a sexual health history, review medications for libido-affecting drugs (SSRIs, antihistamines, oral contraceptives), assess relationship context, and document the acquired and generalized nature of the desire problem. Visit fees range from $75 to $200 depending on the platform.

Shipping to Wyoming Addresses

After a telehealth prescription is issued, the medication can be shipped to any Wyoming address. Brand Vyleesi ships from specialty pharmacies; compounded bremelanotide ships from 503A pharmacies. Both formulations require cold-chain shipping (refrigeration) to maintain peptide stability. Patients should store received product at 36 to 46 degrees Fahrenheit and allow the auto-injector or vial to reach room temperature before injection [1].

Cheapest Way to Get Vyleesi in Wyoming: A Cost Comparison

Patients in Wyoming face three realistic access pathways in 2026. The table below summarizes monthly cost under each scenario.

| Access Pathway | Estimated Monthly Cost | Notes | |---|---|---| | Brand Vyleesi, cash pay | $1,200 | No coupon or card | | Brand Vyleesi, GoodRx coupon | $970 to $1,150 | Varies by pharmacy | | Brand Vyleesi, commercial insurance + savings card | $0 to $50 | Requires PA approval | | Compounded bremelanotide, 503A | ~$140 | Requires valid Rx and licensed compounder |

For uninsured Wyoming residents or those on Medicaid, compounded bremelanotide at roughly $140 per month is the most accessible option. For commercially insured patients whose plans cover Vyleesi after prior authorization, the Palatin savings card can reduce cost to near zero. Patients who have been denied by insurance and find $1,200 prohibitive should ask their telehealth or in-person prescriber to send a prescription to a Wyoming-serving 503A compounding pharmacy.

Wyoming-Specific Resources for HSDD and Vyleesi Access

Wyoming has limited in-state sexual medicine specialty practices. The nearest academic sexual medicine centers are in Denver, Colorado (approximately 100 miles south of Cheyenne) and Salt Lake City, Utah (approximately 440 miles southwest). The North American Menopause Society (NAMS) maintains a provider directory at menopause.org that lists clinicians trained in female sexual health who serve Wyoming patients via telehealth [11].

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 780 addresses sexual health, recommending that OB-GYNs routinely screen for sexual dysfunction including HSDD as part of well-woman care [12]. Wyoming patients who have not been screened by their OB-GYN should request this conversation at their next annual visit.

Wyoming's insurance commissioner can be contacted at the Wyoming Insurance Department if a commercial plan denies Vyleesi without following the plan's own PA criteria. External independent review requests must be filed within 60 days of a final internal denial in Wyoming [6].